Educational information only. Not medical advice, not a diagnosis, and not an offer to sell any product. These are experimental or unapproved substances; we do not provide dosage, sourcing, or use guidance. Consult a licensed clinician. We link to official sources only.
A synthetic 15-amino-acid peptide marketed for gut, tendon and injury recovery. Human evidence is minimal; the FDA staff briefing proposed not adding it to the 503A compounding list.
| Claim | Evidence |
|---|---|
| Gut / ulcerative colitis | R |
| Tendon / injury recovery | C |
| General anti-inflammatory | C |
A synthetic fragment of thymosin beta-4 marketed for tissue repair and recovery. FDA did not identify human administration data; injectable-route risks were flagged.
| Claim | Evidence |
|---|---|
| Wound healing | R |
| Tissue / sports recovery | C |
| Injury repair | C |
One email when regulatory status changes or strong new evidence lands. Health topics only. Unsubscribe anytime.
Educational information only. Not medical advice, not a diagnosis, and not an offer to sell any product. These are experimental or unapproved substances; we do not provide dosage, sourcing, or use guidance. Consult a licensed clinician. We link to official sources only.